英格兰带状疱疹疫苗接种规划实施3年后的效果评价:一项基于人群的研究
该研究基于皇家全科医师学院(Royal College of General Practitioners)哨点初级保健网络164家诊所2005年10月1日至2016年9月30日60-89岁人群数据,评估英格兰带状疱疹疫苗接种规划实施前3年对带状疱疹及带状疱疹后神经痛发病率的影响。常规队列带状疱疹发病率下降35%(发病率比0·65[95%CI 0·60-0·72]),带状疱疹后神经痛下降50%(0·50[0·38-0·67]);补种队列分别下降33%(0·67[0·61-0·74])和38%(0·62[0·50-0·79])。
要点
- 常规队列带状疱疹发病率下降35%,带状疱疹后神经痛下降50%
- 补种队列带状疱疹下降33%,带状疱疹后神经痛下降38%
- 作者认为需传播该规划公共卫生影响以扭转疫苗覆盖下降趋势
研究设计与样本
- 基于人群研究,从皇家全科医师学院(Royal College of General Practitioners)哨点初级保健网络164家诊所提取2005年10月1日至2016年9月30日60-89岁患者带状疱疹和带状疱疹后神经痛就诊数据。
- 采用带人年offset的多变量泊松回归,按年龄、地区、性别、时间段和疫苗资格建模发病率。
主要发现
- 截至2016年8月31日,疫苗 uptake 在近期目标队列为58%,在首个常规队列为72%。
- 三个常规队列接种前3年,带状疱疹发病率下降35%(发病率比0·65[95%CI 0·60-0·72]),带状疱疹后神经痛下降50%(0·50[0·38-0·67])。
- 四个补种队列带状疱疹下降33%(发病率比0·67[95%CI 0·61-0·74]),带状疱疹后神经痛下降38%(0·62[0·50-0·79])。
- 上述下降与疫苗对带状疱疹约62%的效果、对带状疱疹后神经痛70-88%的效果一致。
关键数值与推荐
- 疫苗 uptake:近期目标队列58%,首个常规队列72%(截至2016年8月31日)。
- 常规队列:带状疱疹发病率比0·65(95%CI 0·60-0·72),带状疱疹后神经痛0·50(95%CI 0·38-0·67)。
- 补种队列:带状疱疹发病率比0·67(95%CI 0·61-0·74),带状疱疹后神经痛0·62(95%CI 0·50-0·79)。
- 疫苗效果:对带状疱疹约62%,对带状疱疹后神经痛70-88%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2013, a herpes zoster vaccination programme was introduced in England for adults aged 70 years with a phased catch-up programme for those aged 71-79 years. We aimed to evaluate the effect of the first 3 years of the vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this population. METHODS: In this population-based study, we extracted data from the Royal College of General Practitioners sentinel primary care network on consultations with patients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring between Oct 1, 2005, and Sept 30, 2016, obtaining data from 164 practices. We identified individual data on herpes zoster vaccinations administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated these data to estimate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations. We defined age cohorts to identify participants targeted in each year of the programme, and as part of the routine or catch-up programme. We modelled incidence according to age, region, gender, time period, and vaccine eligibility using multivariable Poisson regression with an offset for person-years. FINDINGS: Our analysis included 3·36 million person-years of data, corresponding to an average of 310 001 patients aged 60-89 years who were registered at an RCGP practice each year. By Aug 31, 2016, uptake of the vaccine varied between 58% for the recently targeted cohorts and 72% for the first routine cohort. Across the first 3 years of vaccination for the three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0·65 [95% 0·60-0·72]) and of postherpetic neuralgia fell by 50% (0·50 [0·38-0·67]). The equivalent reduction for the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0·67 [0·61-0·74]) and 38% for postherpetic neuralgia (0·62 [0·50-0·79]). These reductions are consistent with a vaccine effectiveness of about 62% against herpes zoster and 70-88% against postherpetic neuralgia. INTERPRETATION: The herpes zoster vaccination programme in England has had a population impact equivalent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic neuralgia among 5·5 million eligible individuals in the first 3 years of the programme. Communication of the public health impact of this programme will be important to reverse the recent trend of declining vaccine coverage. FUNDING: Public Health England.
引用
- Amirthalingam G, Andrews N, Keel P, et al. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Health. 2017. PMID: 29276017. doi:10.1016/S2468-2667(17)30234-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。